Αποτελέσματα Αναζήτησης
21 Μαρ 2022 · This narrative review aims to describe the current knowledge on the clinical features of SARS-CoV-2 infection in older adults, focusing on the heterogeneity of clinical presentation and the health-related conditions that might determine a different clinical picture of this disease in advanced age.
19 Μαΐ 2021 · Observational studies including older adults (age ≥ 60 years) with COVID-19 infection and reporting clinical characteristics or outcome were included. Primary outcome was assessing weighted pooled prevalence (WPP) of severity and outcomes.
12 Ιουλ 2024 · Intravenous (IV) infusions at a healthcare facility for 3 consecutive days. Molnupiravir (Lagevrio) Antiviral. Adults. Start as soon as possible; must begin within 5 days of when symptoms start. Taken at home by mouth (orally) Some treatments might have side effects or interact with other medications you are taking.
16 Σεπ 2020 · In the line of therapeutic options for SARS and MERS, this study aims to summarize the current clinical evidence of treatment options for COVID-19. In general, the combination of antibiotics, ribavirin, and corticosteroids was considered as a standard treatment for patients with SARS.
14 Σεπ 2021 · These findings could suggest a connection between the diminished naive TCR repertoire of older individuals before SARS-CoV-2 infection and worsened disease outcome. Lymphopenia
4 Νοε 2022 · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains asymptomatic in 33% to 90% of older adults depending on their immune status from prior infection, vaccination, and circulating strain.
31 Μαρ 2022 · There’s no established treatment specifically for SARS. However, some COVID-19 treatments, such as nirmatrelvir/ritonavir (Paxlovid) and molnupiravir, would likely be effective against SARS.
